not used title

not used title

For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United States remain a leader in biopharmaceutical research and development (R&D). In today’s IP Explained, we’re taking a look at how Hatch-Waxman successfully streamlined the process for generic medicine approvals while preserving incentives for innovation.

The development of new medicines is a lengthy, complex, uncertain and expensive process. In fact, from drug discovery through FDA approval, developing a new medicine takes 10 to 15 years and costs an average of $2.6 billion. In order to balance innovation and affordability, Congress enacted the Hatch-Waxman Act, which provides biopharmaceutical companies with time and incentives to develop safe and effective medicines and generate revenues to put back into future R&D. Under the framework, innovator companies are given a 5-year exclusivity period for new chemical entities during which generic manufactures generally cannot submit FDA applications for new generic versions. Hatch-Waxman also allows for innovators to seek to restore some of the patent term lost due to the FDA approval process.

In addition to fostering biopharmaceutical innovation, Hatch-Waxman increases competition and affordability by creating an abbreviated regulatory approval path for generic products. Abbreviated new drug applications, commonly referred to as ANDAs, allow generic manufacturers to reference the brand manufacturer’s clinical data instead of having to fund their own trials. A defined patent litigation framework and 180-day exclusivity period incentivize generic manufacturers to challenge patents in federal court and improve patient access to generics. Under the framework, generic manufacturers are also protected by a “safe harbor” provision that exempts them from patent infringement liability for development work before the brand drug patent expires.

Prior to the enactment of Hatch-Waxman, only 19 percent of U.S. prescriptions were filled with generics and it took, on average, 3 to 5 years after patent expirations for a generic to enter the market. Since then, the generic pharmaceutical industry has seen enormous growth, and nearly 90 percent of prescriptions are now filled with generics. With this increase in brand and generic competition, Hatch-Waxman created $1.67 trillion in savings from 2007 to 2016.

The Hatch-Waxman Act has successfully balanced innovation and affordability by promoting competition and ensuring the United States continues to deliver life-saving treatments to patients. Strong patent protections give researchers the ability to continue investing in the R&D for new, cutting-edge medicines and approaches that can save and improve millions of lives. We must ensure the U.S. patent system continues to protect these inventions while also incentivizing competition.

Learn more about intellectual property on our IP page and check back for next week’s IP Explained blog.

Tom Wilbur

Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.

Author Twitter

Author LinkedIn

How the biosimilars user fee program supports competition and patients

October 26, 2026

Recognizing the transformative impact of intellectual property

October 13, 2026

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

Mass compounding puts patients at risk

July 16, 2026

Setting the record straight: 3 facts about drug patents

July 13, 2026

New PBM principles don't change the fundamental challenge: Access to lower-cost medicines

July 10, 2026

MFN could disrupt the affordable medicines patients depend on

June 18, 2026

Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings

June 2, 2026

Argentina sets course to enable innovation by rejecting failed patent rules

March 26, 2026

16 years later: How BPCIA continues to expand competition and lower costs

March 23, 2026

Key context is often missing from the debate over the Patent Trial and Appeal Board

March 20, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs

February 2, 2026

Advancing patient care: A look at new medicines approved in 2025

January 30, 2026

How post-approval innovation keeps delivering for patients

December 9, 2025

Knockoffs of FDA-approved drugs put patients at risk

December 1, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

PDUFA: Essential to America’s edge in drug development and patient access

October 31, 2025

Three things to know about Bayh-Dole: Innovation that pays off for taxpayers

October 9, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

PBMs, not patents, are blocking access to lower-cost medicines

July 23, 2025

New report: How intellectual property drives U.S. innovation and biopharma's impact

June 30, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers

April 30, 2025

USTR 2025 Special 301 Report corrects course

April 29, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

How the IRA is impacting the generic drug market

April 8, 2025

3 myths critics get wrong about intellectual property

March 28, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

Major drug compounder is spending millions on misleading Super Bowl ad

February 5, 2025

PhRMA submission calls for USTR to correct course on trade policy, enforcement

October 18, 2024

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

September 24, 2024

40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Biden Administration report debunks myths around patent “evergreening” and “thickets”

September 3, 2024

What to know about the latest effort to break patents using a legally dubious avenue

August 21, 2024

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation

August 12, 2024

More oversight needed of unapproved medicines that threaten patients’ health

August 1, 2024

PhRMA launches education campaign on the benefits of America's IP system

June 26, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Experts discuss the value of IP at Senate Judiciary Committee hearing

May 28, 2024

World Trade Week 2024: Time for a more ambitious U.S. trade agenda

May 23, 2024

The use of real-world data in drug development

May 13, 2024

New analysis: Accelerated approval pathway is changing lives in underserved communities

April 30, 2024

World IP Day 2024: Supporting an innovative and sustainable future

April 26, 2024

International meetings hold big implications for Americans and our innovation ecosystem

February 26, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines

January 31, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership

January 29, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high

January 23, 2024

Florida’s importation plan puts patients in danger

January 5, 2024

The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings

December 19, 2023

The White House continues to attack American innovation

December 15, 2023

Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation

November 29, 2023

Misuse of march-in could stifle innovation

November 27, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

PhRMA submission: USTR needs more ambition to combat unfair trade barriers

October 24, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain

September 12, 2023

Decentralized clinical trials and the future of drug development

August 9, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

How FDA’s modernization strategy could improve drug development

June 20, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Setting the record straight on accelerated approval

May 22, 2023

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

May 18, 2023

Setting the record straight on the Bayh-Dole Act and March-in

May 10, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

April 13, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

FDA should remain the authority on the safety and effectiveness of medicines

April 12, 2023

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

March 30, 2023

U.S. biopharmaceutical exports support jobs, innovation

March 20, 2023

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

March 13, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

U.S. must address IP and market access barriers abroad to protect American innovation

January 31, 2023

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

January 17, 2023

What you should know about real-world evidence and drug development

December 19, 2022

Three things to know about the accelerated approval pathway

December 12, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Six ways I-MAK is lying about biopharma patents

November 16, 2022

TRIPS waiver expansion risks public health

November 14, 2022

Expanding the WTO intellectual property waiver will hurt American jobs

November 9, 2022

PhRMA submission to USTR calls for urgent defense of American innovation abroad

November 1, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

PDUFA and BsUFA reauthorizations are wins for patients

October 5, 2022

New report ignores benefits of patent system to innovation and patients

September 30, 2022

Partnerships are driving global COVID-19 treatment access

September 22, 2022

The dangers of expanding the TRIPS waiver

September 19, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

Patent policy changes proposed by USPTO and FDA would leave patients behind

July 22, 2022

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

July 15, 2022

Word of the Month: Biomarkers and surrogate endpoints

July 11, 2022

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

May 23, 2022

Ensuring timely reauthorization of PDUFA and BsUFA

May 11, 2022

Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad

April 29, 2022

PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

April 13, 2022

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

March 17, 2022

The importance of timely PDUFA and BsUFA reauthorization

February 3, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

Protecting U.S. innovation abroad to support economic and pandemic recovery

February 1, 2022

ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

January 26, 2022

Legislation threatens patent protections and future innovation

January 12, 2022

Global COVID-19 vaccination matters now and for the future

November 29, 2021

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

November 1, 2021

PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19

October 29, 2021

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

September 28, 2021

Meeting Tomorrow: Looking ahead to PDUFA VII

September 27, 2021

Patients and innovators lose if the government pursues ‘march-in’

September 7, 2021

The impact of monoclonal antibodies and COVID-19 recovery

September 2, 2021

PDUFA VII is critical for future biopharmaceutical innovation and for patients

August 23, 2021

Supporting country readiness to boost global vaccine access

August 12, 2021

Ensuring global vaccine equity requires eliminating trade and regulatory barriers

August 5, 2021

Increasing global access to vaccines by optimizing production

July 29, 2021

Dose sharing as a part of the COVID-19 global vaccine equity strategy

July 20, 2021

Promoting global vaccine equity while protecting innovation

July 15, 2021

IP Explained: How does the U.S. patent process work?

June 24, 2021

How strengthening the biosimilar marketplace benefits patients

May 18, 2021

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

May 14, 2021

The Biden Administration allows politics to upend a pragmatic pandemic response

May 14, 2021

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research

May 12, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

American leadership on innovation policy is essential to global health progress

May 4, 2021

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

April 9, 2021

Intellectual property is the key to vaccine development, manufacturing and technology sharing

March 5, 2021

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

February 12, 2021

Preserving U.S. innovation worldwide is more important than ever

January 29, 2021

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

January 26, 2021

New video: See how strong IP protections lead to stronger treatments for patients

November 9, 2020

Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

September 30, 2020

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

September 16, 2020

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

July 22, 2020

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

July 13, 2020

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

July 2, 2020

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

June 5, 2020

IP Explained: Intellectual property system working to combat COVID-19

May 28, 2020

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

May 4, 2020

The continued imperative to protect U.S. innovation worldwide

April 29, 2020

Nearly 400 cell and gene therapies in development to target a broad range of diseases

March 10, 2020

IP Explained: Four key takeaways from new Bayh-Dole white paper

February 19, 2020

Trump administration must defend and protect U.S. innovation

February 6, 2020

ICYMI: 2019 brings innovative medicines to patients

January 17, 2020

PhRMA comments to Congress on Cures 2.0 call to action

December 18, 2019

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

November 4, 2019

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

October 9, 2019

IP Explained: Four things to know about the Bayh-Dole Act

September 13, 2019

IP Explained: Three forms of IP protections for medicines

August 27, 2019

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

August 6, 2019

IP Explained: Understanding biopharmaceutical innovation

July 30, 2019

IP Explained: Why IP protections are important for biologic medicines

July 18, 2019

IP Explained: What is Section 101 and why reforms are needed

June 26, 2019

Guest Post: Using the patient voice to go boldly

May 30, 2019

World Trade Month: How we can expand world-class pro-innovation standards

May 22, 2019

IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry

May 2, 2019

IP Explained: What they are saying on the importance of strong intellectual property protections

April 24, 2019

IP Explained: Why patents are so critical to biopharmaceutical innovation

April 16, 2019

New report: Using march-in authority would jeopardize U.S. innovation

March 19, 2019

Special 301 submission calls for a level playing field for American innovators

March 13, 2019

Guest post: Hearing from patients on Rare Disease Day

February 28, 2019

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

February 28, 2019

Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement

February 27, 2019

Why state drug importation pilot programs don’t work

February 8, 2019

Putting 2018 medicine approvals in context

January 23, 2019

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

November 2, 2018

FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies

October 16, 2018

Balancing innovation and competition in the biologics marketplace

October 11, 2018

Five myths about global efforts to combat tuberculosis

September 20, 2018

Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines

July 25, 2018

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

June 19, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018

To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements

May 10, 2018

Spending on medicines grew less than one percent in 2017

April 19, 2018

What is inter partes review and why does it matter?

March 16, 2018

Rare Disease Day: Unmet need inspires innovation

February 28, 2018

Innovation comes in many forms, including new and expanded uses of existing medicines

January 29, 2018

ICYMI: Why 2017 medicine approvals matter

January 12, 2018

New surveys find payers and providers want more data from biopharmaceutical companies

December 6, 2017

Supporting opportunities for enhanced competition in the marketplace

November 22, 2017

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

October 12, 2017

Biopharma leads sustained economic growth driven by IP-intensive industries

September 26, 2017

Opportunities to build upon enhanced competition for medicines in the marketplace

July 27, 2017

Why reauthorization of PDUFA matters

July 13, 2017

Foreign government price setting by any name harms innovation and access to medicines

June 6, 2017

A critical opportunity to prevent prescription drug abuse

June 2, 2017

Compulsory licensing: A misused and abused international trade law

May 16, 2017

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

May 5, 2017

Illegal trade barriers discriminate against U.S. innovators

May 2, 2017

Trading fair means upholding the law: A focus on patents

April 18, 2017

Enforcing unmet trade obligations protects U.S. innovation

April 11, 2017

NAFTA tribunal fails to rule on Canada’s patent utility doctrine

April 4, 2017

Guest Post: The importance of a modern FDA in drug discovery

March 22, 2017

PhRMA urges USTR to protect American innovators abroad

February 10, 2017